weight-loss drug by
Sanofi-Aventis called
Acomplia may carry a significant risk
company's website,
FDA reviewers noted that while
Acomplia did appear
FDA panel rejects
Sanofi-Aventis'
Acomplia drug. By John Letzing, MarketWatch
rejected
Acomplia, a weight-loss drug from French drug maker
Sanofi-Aventis SA,
By a unanimous vote, a panel of experts convened by the
FDA just rejected
Sanofi-Aventis's weight-loss drug, known in Europe as
Acomplia, Dow Jones reports. The
FDA Has Concerns About Suicide, Depression and Other Risks Tied to
Sanofi-Aventis'
Acomplia drug maker,
FDA said patients taking
Acomplia daily showed
News and reviews about diet drug rimonabant /
Acomplia / Zimulti. Site NOT affiliated with or endorsed by
Sanofi, the
Acomplia / Zimulti trademark owner.
FDA has concerns about suicide, depression and other risks tied to
Sanofi-Aventis'
Acomplia said
Sanofi-Aventis' obesity treatment
Acomplia may trigger
Finegenerics is online Generic Drugs resource containing quality information on drugs, usage, precautions, side
acomplia, a weight-loss drug
Sanofi-Aventis has received an approvable letter from the
FDA for
Acomplia for
FDA reached its decision,
Sanofi-Aventis had been boasting of
Acomplia's
News and reviews about diet drug rimonabant /
Acomplia / Zimulti. Site NOT affiliated with or endorsed by
Sanofi, the
Acomplia / Zimulti trademark owner.
Acomplia Waiting Game Continues,
Sanofi now expects the
FDA to act on the drug in late April rather than this year. Insightful financial news and analysis at TheStreet.
warily to a U.S. health review of anti-obesity pill
Acomplia, highlighting its
Sanofi drops after
FDA staff comments on
Acomplia. Tue Jun 12, 2007 5:41am
Sanofi-Aventis's drug
Acomplia helps patients lose weight but appears to
approved,
Sanofi will call it "Zimulti," in the U.S. because the
FDA ruled that
Regulators on Monday said
Sanofi-Aventis' obesity treatment
Acomplia may trigger suicidal behavior and other psychological side effects in some patients.
Regulators on Monday said
Sanofi-Aventis' obesity treatment
Acomplia may trigger suicidal behavior and other psychological side effects in some patients.
Regulators on Monday said
Sanofi-Aventis' obesity treatment
Acomplia may trigger suicidal behavior and other psychological side effects in some patients.
Acomplia | Zimulti, which will be tabled at
FDA's Endocrinologic and Metabolic Drugs advisory panel on June 13 for its approval for sale in the U.S
agency will approve
Acomplia, especially since
FDA officials usually follow the
Sanofi-Aventis was going to call its pill Zimulti in the US, because the
FDA
PARIS (AFX)
Sanofi-Aventis said the US Food and Drug Administration has extended its review of anti-obesity drug
Acomplia by three months to July 27.
acomplia sanofi. Post Reply. Posted by: kitybo. 06/20/2007, 00:45:59
treatment
acomplia short term rimonabant labelling
acomplia fda acomplia side
Sanofi- Aventis SA's weight loss pill
Acomplia shouldn't be approved in the
FDA panel rejects
Sanofi diet pill, cites psychiatric risks. By Bloomberg News
The Motley Fool Positive study results are a load off the company's mind.
the
FDA has set April 26 as the new date to review
Acomplia and give
Sanofi a
sanofi aventis
acomplia The individuals taking
Acomplia diet and EU
Acomplia Patients on Diet Drug
Acomplia functions by
FDA Meeting on the potential side
Regulators on Monday said
Sanofi-Aventis' obesity treatment
Acomplia may trigger suicidal behavior and other psychological side effects in some patients.
The
FDA in February granted conditional approval for
Acomplia as a weight
Sanofi-Aventis executives have been saying since late February that the
FDA
PARIS, June 14 (Reuters)
Sanofi-Aventis <SASY.PA> shares fell on Thursday after a U.S. health panel recommended
said it would work with the
FDA to
FDA issued an approvable letter for
Acomplia in February, to which
Sanofi responded in October.
Acomplia, a first-in-class cannabinoid type 1 receptor
FDA panel rejects
sanofi-aventis'
Acomplia drug (MarketWatch)
FDA panel rejects
sanofi weight loss drug
Acomplia (Morningstar)
Tuesday indicates
Sanofi-Aventis' weight-loss drug candidate
Acomplia can help
the odds of
Acomplia getting full approval by the
FDA's February deadline at
failed to win approval from an
FDA advisory panel, mainly because of fears that
also asked
Sanofi-Aventis to abandon the name
Acomplia because regulators
After Aventis,
FDA weighs
Acomplia's side effects.
FDA approves
Sanofi's Taxotere for head and neck cancer. Ketek gets new warnings, limit on use